

Objectives of MPN&MPNr-EuroNet

The main objectives of MPN&MPNr-EuroNet are:

1. To foster, formalize and support collaborations between European MPN experts to optimize and standardize the molecular diagnosis of MPNs, congenital erythrocytosis and hereditary thrombocytosis (MPN-related diseases or MPNr) in Europe.
2. To optimize and standardize the molecular detection and quantification of the most frequent mutations in MPNs: the *JAK2*V617F mutation, *JAK2* exon 12 mutations, *MPL*W515K/L mutations, and *CALR* mutations.
3. To organize and centralize the investigation of rare mutations in the *HIF2A*, *PHD2*, *VHL*, *EPOR*, *MPL*, *JAK2* and *THPO* genes, for the diagnosis of congenital erythrocytosis and hereditary thrombocytosis.
4. To foster research and innovation in the field of MPNs and related hereditary diseases.

MPN&MPNr-EuroNet 31 participating countries (in bright blue on the map below)

Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, The Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, The Republic of Macedonia, The Netherlands, Norway, Poland, Portugal, Romania, Russia, The Republic of Serbia, Spain, Sweden, Switzerland, Slovakia, Turkey, The United Kingdom, USA.



New members are invited to join and participate in MPN&MPNr-EuroNet working groups. To register as new member, please click on “To become a member” on the Home page, then follow instructions.